We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
China’s National Medical Products Administration (NMPA) has banned the importation, sale and use of Bristol-Myers Squibb’s cancer blockbuster Abraxane (nanoparticle albumin-bound paclitaxel) following an inspection in the U.S. Read More
The Canadian government has passed a law that temporarily speeds up its process for overriding drug patents, to ensure accessibility to medically necessary products during the coronavirus pandemic. Read More
The FDA has said it will allow convalescent plasma to be used as an emergency treatment for patients with serious or immediately-life threatening COVID-19. Read More
India has banned almost all exports of hydroxychloroquine to protect the nation’s domestic supply of the malaria drug considered a possible treatment for COVID-19. Read More
A New York federal judge has dismissed a whistleblower suit alleging that Novartis paid physicians kickbacks to prescribe its multiple-sclerosis drug Gilenya. Read More
The FDA has removed an Indian supplier of hydroxychloroquine and chloroquine APIs from an import alert to free up imports of the potential COVID-19 treatments from two of its plants. Read More
Sponsors who fail to meet certain Risk Evaluation and Mitigation Strategy (REMS) requirements won’t face FDA action during the COVID-19 outbreak, the agency announced. Read More
State pharmacy boards in Idaho, Ohio, Nevada and Texas are restricting prescriptions of certain drugs that may hold potential in treating the coronavirus, including chloroquine and hydroxychloroquine, following a spike in demand. Read More
“There are many reasons that make demonstrating effectiveness extremely challenging” for drugs intended to treat such rare diseases, the agency said. Read More